Immune checkpoint inhibitors (ICIs) disrupt the signaling of programmed death 1 (PD-1) receptors expressed on T cells and the PD, PD-L1, and PD-L2 ligands expressed on tumor cells [3,4,5]. The gene discussed is CD274; the disease is neoplasm.